Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck Millipore Launches Eshmuno® A Media and Chromabolt™ Columns

Published: Wednesday, September 18, 2013
Last Updated: Wednesday, September 18, 2013
Bookmark and Share
Eshmuno® A is a rigid, high capacity, acid and alkaline resistant Protein A affinity chromatography media.

Merck Millipore has introduced two additions to the Company's comprehensive chromatography portfolio to further accelerate downstream purification and improve process efficiency.

Eshmuno® A is a rigid, high capacity, acid and alkaline resistant Protein A affinity chromatography media for the purification of monoclonal antibodies and other Fc-containing proteins.

Higher binding capacities offered by Eshmuno® A media in comparison with other commercially available Protein A media delivers increased productivity and lower costs.

Eshmuno® A media can be cleaned and sanitized under acid and/or alkaline conditions while maintaining high dynamic binding capacity at high flow rates with no significant change in product purity.

In addition, the media offers an orthogonal solution for aggregate removal at both the front and tail ends of the elution peak from the Protein A column. This property of the Eshmuno® A media is advantageous in reducing the burden of subsequent chromatography steps typically used in the purification of Fc-containing proteins.

"Optimizing the particle size and pore size of the Eshmuno® base matrix along with the immobilization of our proprietary ligand enables a significant increase in dynamic binding capacity," states David Beattie, Ph.D., head Biopharm Process Solutions R&D, Merck Millipore.

Beattie continued, "This allows for higher loading of the Fc-containing protein being purified, maximizing column throughput and improving process economics. The ability to increase capacity and throughput with the Eshmuno® A media also allows our customers to more effectively process the high titers coming from upstream processing."

Chromabolt™ prepacked, pre-validated chromatography columns, available with a range of Merck Millipore chromatography resins, are designed for early clinical stage manufacturing.

Pre-validation indicates the columns meet bioburden, endotoxin, HETP and asymmetry specification for the resin. Offered in 3 sizes - 10, 20 and 32 cm i.d. - Chromabolt™ prepacked columns eliminate laborious packing and equipment cleaning.

The columns are currently available packed with Fractogel® SO3, Fractogel® TMAE HiCap, and Eshmuno® S resins. Going forward, additional resins will be made available in the Chromabolt™ format.

The prepacked columns are compatible with all currently available chromatography systems and connectors, have easily accessible inlets and outlets, and offer faster set-up times compared to traditional columns. Ergonomic and easily transportable by a single person, the 20 cm and 32 cm sizes are on wheels.

"Downstream processes must become faster, more lean, and cost-effective," notes Vin Donovan, head of Biopharm Process Solutions business field, Merck Millipore. "With Chromabolt™ prepacked columns, we help customers accelerate pilot and early stage clinical scale manufacturing and lower their costs by eliminating manual packing and equipment cleaning."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novel Mechanism for Activation of SIRT1
Assay format allows for simple, sensitive detection of sirtuin activity on any desired substrate.
Wednesday, April 24, 2013
Merck Millipore Announces New Genomic Biomarker Services
Genetic and epigenetic technologies added to established CRO services for biomarker development, validation and testing.
Wednesday, December 05, 2012
Merck Millipore Announces Opening of its GMP Bioproduction Facility in France
Enables accelerated process development and production of proteins/monoclonal antibodies.
Friday, September 21, 2012
Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
“Amazing Protein Diversity” Discovered in Maize
The genome of the corn plant – or maize, as it’s called almost everywhere except the US – “is a lot more exciting” than scientists have previously believed. So says the lead scientist in a new effort to analyze and annotate the depth of the plant’s genetic resources.
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Nanoprobe Enables Measurement of Protein Dynamics in Living Cells
Mass. General and Harvard researchers use device to measure how anesthetic affects levels of Alzheimer's-associated proteins.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
A New Tool Brings Personalized Medicine Closer
Scientists from EPFL and ETHZ have developed a powerful tool for exploring and determining the inherent biological differences between individuals, which overcomes a major hurdle for personalized medicine.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!